News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,789 Results
Type
Article (43053)
Company Profile (458)
Press Release (683261)
Multimedia
Podcasts (104)
Webinars (19)
Section
Business (209052)
Career Advice (2029)
Deals (36066)
Drug Delivery (108)
Drug Development (83781)
Employer Resources (174)
FDA (16569)
Job Trends (15154)
News (353531)
Policy (33224)
Tag
Academia (2646)
Accelerated approval (17)
Adcomms (28)
Allergies (115)
Alliances (51108)
ALS (134)
Alzheimer's disease (1589)
Antibody-drug conjugate (ADC) (193)
Approvals (16616)
Artificial intelligence (385)
Autoimmune disease (49)
Automation (25)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (19)
Biosimilars (143)
Biotechnology (332)
Bladder cancer (119)
Brain cancer (42)
Breast cancer (438)
Cancer (3502)
Cardiovascular disease (295)
Career advice (1704)
Career pathing (32)
CAR-T (220)
CDC (41)
Cell therapy (587)
Cervical cancer (30)
Clinical research (69448)
Collaboration (1270)
Company closure (4)
Compensation (866)
Complete response letters (48)
COVID-19 (2724)
CRISPR (77)
C-suite (511)
Cystic fibrosis (128)
Data (3954)
Decentralized trials (2)
Denatured (34)
Depression (98)
Diabetes (405)
Diagnostics (6568)
Digital health (30)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (184)
Drug pricing (150)
Drug shortages (29)
Duchenne muscular dystrophy (188)
Earnings (89825)
Editorial (49)
Employer branding (21)
Employer resources (151)
Events (118405)
Executive appointments (925)
FDA (18810)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (5)
Frontotemporal dementia (12)
Funding (1131)
Gene editing (161)
Generative AI (26)
Gene therapy (477)
GLP-1 (888)
Government (4674)
Grass and pollen (5)
Guidances (332)
Healthcare (19187)
HIV (44)
Huntington's disease (34)
IgA nephropathy (54)
Immunology and inflammation (210)
Immuno-oncology (16)
Indications (51)
Infectious disease (2929)
Inflammatory bowel disease (170)
Inflation Reduction Act (14)
Influenza (82)
Intellectual property (173)
Interviews (314)
IPO (16892)
IRA (51)
Job creations (3710)
Job search strategy (1436)
Kidney cancer (13)
Labor market (66)
Layoffs (557)
Leadership (25)
Legal (8014)
Liver cancer (86)
Longevity (11)
Lung cancer (501)
Lymphoma (248)
Machine learning (25)
Management (59)
Manufacturing (548)
MASH (121)
Medical device (13725)
Medtech (13742)
Mergers & acquisitions (20001)
Metabolic disorders (1022)
Multiple sclerosis (127)
NASH (19)
Neurodegenerative disease (185)
Neuropsychiatric disorders (50)
Neuroscience (2504)
NextGen: Class of 2025 (6758)
Non-profit (4562)
Now hiring (54)
Obesity (499)
Opinion (252)
Ovarian cancer (120)
Pain (146)
Pancreatic cancer (155)
Parkinson's disease (216)
Partnered (25)
Patents (379)
Patient recruitment (276)
Peanut (53)
People (59476)
Pharmaceutical (85)
Pharmacy benefit managers (23)
Phase I (21799)
Phase II (30656)
Phase III (22625)
Pipeline (2519)
Policy (246)
Postmarket research (2602)
Preclinical (9364)
Press Release (67)
Prostate cancer (180)
Psychedelics (49)
Radiopharmaceuticals (274)
Rare diseases (589)
Real estate (6041)
Recruiting (69)
Regulatory (23728)
Reports (51)
Research institute (2435)
Resumes & cover letters (352)
Rett syndrome (11)
RNA editing (15)
RSV (60)
Schizophrenia (118)
Series A (190)
Series B (143)
Service/supplier (11)
Sickle cell disease (77)
Special edition (24)
Spinal muscular atrophy (154)
Sponsored (35)
Startups (3786)
State (2)
Stomach cancer (15)
Supply chain (90)
Tariffs (75)
The Weekly (68)
Vaccines (896)
Venture capital (62)
Weight loss (324)
Women's health (54)
Worklife (18)
Date
Today (131)
Last 7 days (495)
Last 30 days (2280)
Last 365 days (31576)
2025 (23072)
2024 (36299)
2023 (41015)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (742)
Alabama (76)
Alaska (7)
Arizona (270)
Arkansas (14)
Asia (39963)
Australia (6632)
California (8873)
Canada (2723)
China (818)
Colorado (372)
Connecticut (390)
Delaware (237)
Europe (87559)
Florida (1302)
Georgia (291)
Hawaii (2)
Idaho (60)
Illinois (712)
India (40)
Indiana (421)
Iowa (19)
Japan (284)
Kansas (119)
Kentucky (33)
Louisiana (17)
Maine (66)
Maryland (1171)
Massachusetts (6583)
Michigan (272)
Minnesota (521)
Mississippi (4)
Missouri (103)
Montana (31)
Nebraska (25)
Nevada (101)
New Hampshire (73)
New Jersey (2440)
New Mexico (30)
New York (2406)
North Carolina (1280)
North Dakota (9)
Northern California (4010)
Ohio (268)
Oklahoma (17)
Oregon (40)
Pennsylvania (1858)
Puerto Rico (18)
Rhode Island (44)
South America (1113)
South Carolina (43)
South Dakota (1)
Southern California (3407)
Tennessee (142)
Texas (1360)
United States (32414)
Utah (259)
Virginia (217)
Washington D.C. (76)
Washington State (751)
West Virginia (4)
Wisconsin (78)
Wyoming (1)
726,789 Results for "corcept therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ALS
Corcept Claims Survival Benefit in ALS Despite Missed Endpoint
Analysts at Truist Securities called the mid-stage data a “mixed bag,” also flagging gastrointestinal adverse events. However, the readout is unlikely to be “incremental” to Corcept’s overall stock narrative.
June 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
September 11, 2025
·
4 min read
Press Releases
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 31, 2025
·
10 min read
Press Releases
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 24, 2025
·
1 min read
Press Releases
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
September 23, 2025
·
4 min read
Press Releases
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
May 5, 2025
·
11 min read
Press Releases
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
July 15, 2025
·
4 min read
Press Releases
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
April 28, 2025
·
1 min read
Press Releases
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
March 10, 2025
·
3 min read
Press Releases
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
April 21, 2025
·
4 min read
1 of 72,679
Next
